Gene editing has had a big week in the spotlight. Here’s what’s going on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: biotechnology
STAT+: Life science investors close nearly $6 billion in new funds
Biotech and life sciences investors continue to draw in new funds even as the biotech…
STAT+: DeepMind touts AlphaFold’s new skills as protein-folding AI models face off
On Tuesday, Google DeepMind and Isomorphic Labs announced a significant progress update on the next…
Sarepta’s disappointing data put the FDA in a difficult spot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Eli Lilly to pay $200 million for Beam’s share of drugs from gene-editing firm Verve
Eli Lilly said Tuesday that it will pay $200 million to gene-editing firm Beam Therapeutics…
How skeptical should you be of an after-the-fact subgroup analysis in a failed clinical trial?
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc…
STAT+: Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease
The Food and Drug Administration is convening a meeting of outside experts on Tuesday to…
.jpg)
STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial
Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to…
STAT+: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems
Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of…
Your Monday morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: What to know about Sarepta’s upcoming data on its Duchenne gene therapy
In the next few weeks, Sarepta Therapeutics will release new data that could change the…
STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio
It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO…
STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show
The Food and Drug Administration said on Friday that it has some safety concerns about…
STAT+: Why Sanofi got shellacked
Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion…
.jpg)
Regeneron gene therapy improves hearing in child
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer
And so, another working week will soon draw to a close. Not a moment too…
STAT+: In major test for prime editing, scientists succesfully correct mutations in monkeys
Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called…
STAT+: ARPA-H head Renee Wegrzyn on the agency’s new Cambridge hub and plans for cancer research
CAMBRIDGE, MASS. — In an area long known as an epicenter of innovation and investment…
Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise
How do cancer drugs work? What makes biotech stocks go up? And why are venture…
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show
A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler,…
STAT+: Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease
An experimental treatment for Alzheimer’s disease that removes a toxic protein called tau from brain…
The XBI biotech index hit its lowest point since 2018. No one knows what comes next.
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Massachusetts biotechs seek to piggyback on weight loss drug boom
The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and…
Why AstraZeneca’s CEO is accusing British tabloids of ‘fake news’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Startup launches with $245 million for twice yearly asthma treatment
A new biotech has raised $245 million to test a new asthma medication that could…
STAT+: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole
Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about…
Johnson & Johnson antiviral pill for dengue shows early efficacy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA clears Verve to begin U.S. study of gene-editing treatment for high cholesterol
Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration…
STAT+: Eli Lilly, riding a hot streak, expects to double planned employment in Boston research center
Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the…
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer
MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients…
Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients
Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…
STAT+: How biotech deal-making really works behind the scenes, according to founders
What does it feel like to run a biotech startup and then get “the call”…
STAT+: GSK CEO on pharma giant’s new direction: ‘We’re in the business of preventing and treating disease’
The story of GSK is one of reinvention, CEO Emma Walmsley said at the STAT…
STAT+: The future of Biogen: Pragmatism, ‘a few moonshots,’ and no Twinkies
Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher…
Listen: Live from the 2023 STAT Summit
What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how…
STAT+: Startup Laronde merges with another biotech in wake of data integrity issue
RNA medicines startup Laronde is merging with another startup in the wake of a scientific…
STAT+: Beam Therapeutics to lay off 20% of its staff, reevaluate programs as it cuts costs
Beam Therapeutics said Monday morning it would lay off 20% of its staff — or…
What if there’s no market for a CRISPR cure?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer
Europe’s major cancer research conference kicks off in Madrid on Friday, with headline — and…
STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs
During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but…
Zuckerberg and Chan announce a New York biohub to build disease-fighting cellular machines
Meta founder Mark Zuckerberg and his wife, pediatrician and philanthropist Priscilla Chan, will announce on…
STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups…
STAT+: Biotech investors push to extend time before pills are subject to price negotiations
The fight over drug prices is far from over. Investors in biopharma companies, who lobbied…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease….
As Pfizer slashes revenue projections, Moderna says it “remains comfortable”
Want to stay on top of the science and politics driving biotech today? Sign up to get…